Get started
Vistagen Therapeutics, Inc.Vistagen Therapeutics, Inc.Vistagen Therapeutics, Inc.

Vistagen Therapeutics, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

VTGN trade ideas

VTGN - Bottom Biotech PlayVistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. The company's pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines. The portfolio of the company includes PH94B, a novel neuroactive nasal spray; PH10, an odorless, fast-acting synthetic neurosteroid and AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR) which is the Company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID) and epilepsy. Disclaimer: This is not financial advice. Shares Outstanding: 24.29 million. Relative Volume on March 28, 2024: Noted. This implies an evaluation of trading volume in relation to its average volume, suggesting a nuanced perspective on the stock's activity. General Strategy: This appears to be a more gradual investment strategy. Success hinges on maintaining a bullish sentiment across the broader market. A market correction could potentially undermine this strategy's effectiveness. Key Resistance Levels: Identified between $5.80 and $6.00. Breaking above this range is critical for further upward momentum. Stop-Loss Strategy: Set just below $5.00. This aims to limit potential losses should the stock's price fall unexpectedly. Target Prices: Estimated around $7.00, suggesting where to potentially take profits based on the analysis. Chart Analysis: It is indicated that a significant portion of the analysis and decision-making data is visualized on the provided chart. Trading Caution: Emphasizes the importance of careful consideration and risk management in trading decisions. Reminder: Always conduct your own research and consider multiple perspectives before making investment decisions.
NASDAQ:VTGNLong
by meitshels_smell_trades
Vistagen Therapeutics Inc - VTGNFollow the trend! PALISADE Phase 3 Clinical Program for PH94B: The PALISADE Phase 3 clinical program has been initiated to evaluate the efficacy and safety of PH94B for the acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). PH94B is an odorless, rapid-onset, investigational pherine nasal spray with a unique mechanism of action, working differently than all existing therapies for SAD. There is currently no U.S. Food and Drug Administration (FDA) approved acute treatment of anxiety for adults with SAD. PALISADE-1 is the first clinical trial in the program and is being conducted across approximately 18 sites in the U.S., with a target of approximately 200 randomized subjects. Dr. Michael Liebowitz, a Columbia University psychiatrist, former director and founder of the Anxiety Disorders Clinic at the New York State Psychiatric Institute, director of the Medical Research Network in New York City, and creator of the Liebowitz Social Anxiety Scale (LSAS), is serving as Principal Investigator of the trial. Topline results from PALISADE-1 are anticipated in mid-2022. I'm looking forward to VTGN speaking at Canaccord's conference next week. 5 Wall Street analysts have issued ratings and price targets for VistaGen Therapeutics in the last 12 months. Their average twelve-month price target is $6.50, predicting that the stock has a possible upside of 132.97%. The high price target for VTGN is $9.00 and the low price target for VTGN is $5.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
NASDAQ:VTGNLong
by aschnell001
$VTGN PT 4.50-8 and higherVistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.
NASDAQ:VTGNLong
by BADQOMOCAWGOWLD
$VTGN can rise in the next daysContextual immersion trading strategy idea. VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The demand for shares of the company looks higher than the supply. This and other conditions can cause a rise in the share price in the next days. So I opened a long position from $2,96; stop-loss — $2,45. Information about take-profits will be later. Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:VTGNLong
by KozakHlib
Jefferies $PRTA buy recommendation with price target of $6Why VistaGen Therapeutics Stock Soared yesterday The big jump came after Jefferies analyst Andrew Tsai initiated coverage on the stock with a buy recommendation. Tsai also set a one-year price target of $6, nearly three times the price of VistaGen's shares at the market close on Wednesday. Why bullish? Tsai really likes the potential for VistaGen's lead pipeline candidate PH94B . It's a nasal spray that VistaGen is evaluating in phase 2 studies targeting multiple neurological disorders. The company has already reported positive data from one of those studies, with PH94B showing promise in treating acute social anxiety disorder . There are still plenty of risks for PH94B and VistaGen's two other pipeline candidates. www.fool.com
NASDAQ:VTGN
by AlenCiken
Vistagen (VTGN): Long-term Game-changer* This is not financial advice. This is my non-expert opinion. * Vistagen ( NASDAQ:VTGN ) is a clinical stage biopharmaceutical company with long-term potential. I believe it's technology is similarly game-changing the way I believe NanoFlu for Novavax is (www.novavax.com) ( ). It could have positive outcomes for the world. I hope that their tech comes to fruition. Their pipeline includes Neuroactive nasal sprays that don't involve benzodiazepine and its associated side effects. I hope they succeed because it could change the way patients with anxiety or depression-related disorders are treated. Vistagen: www.vistagen.com Pipeline: www.vistagen.com PH94B Neuroactive Nasal Spray is their most advanced candidate, which is currently in Stage 3 clinical trials. I encourage anyone who wants to do their own research. This animated demonstration was very informative for me www.youtube.com Keep an eye out for this company.
NASDAQ:VTGNLong
by traderman001
VTGN - DAILY CHARTHi, today we are going to talk about VistaGen Therapeutics Inc and its current landscape. VistaGen Therapeutics Inc despite the high volatility of this penny stock it could be hiding a gold mine as the company has received Fast Track designation by the FDA for the development of the company's PH94B neuroactive nasal spray for on-demand treatment of social anxiety disorder. The clinical-stage biopharmaceutical company has been developing this new generation of medicines for central nervous system diseases and disorders that don't have their needs by the currently products on the market, with this FDA designation PH94B that it's preparing to enter on its phase 3 development, has the potential of being next VistaGen gem, since could meet the need of 15 million adults that in the U.S (6.8% of the population), suffers of social anxiety disorder*, a context that made VistaGen Therapeutics worth to follow closely. Thank you for reading and leave your comments if you like. To have access to our exclusive contents, join the Traders Heaven today! Link Below. *ADAA - Anxiety and Depression Association of America Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
NASDAQ:VTGN
by Igor-Silva
$VTGN Bullish Momentum Can Trendline Hold? VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA. Short Interest: 2.08M 09/30/19 P/E Current -1.51 P/E Ratio (with extraordinary items) -2.09 Average Recommendation: OVERWEIGHT Average Target Price: 2.35
NASDAQ:VTGNLong
by DEXWireNews